Quipt Home Medical (QIPT)
(Delayed Data from NSDQ)
$2.69 USD
+0.04 (1.51%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $2.70 +0.01 (0.37%) 7:58 PM ET
5-Strong Sell of 5 5
A Value B Growth D Momentum A VGM
Income Statements
Fiscal Year end for Quipt Home Medical Corp falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 222 | 140 | 102 | 73 | 61 |
Cost Of Goods | 62 | 33 | 28 | 20 | 18 |
Gross Profit | 160 | 107 | 74 | 53 | 43 |
Selling & Adminstrative & Depr. & Amort Expenses | 156 | 102 | 76 | 52 | 46 |
Income After Depreciation & Amortization | 4 | 5 | -1 | 1 | -3 |
Non-Operating Income | 0 | 0 | -6 | -3 | -3 |
Interest Expense | 7 | 2 | 2 | 2 | 2 |
Pretax Income | -3 | 3 | -9 | -4 | -7 |
Income Taxes | 0 | -2 | -3 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -3 | 5 | -6 | -4 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | -1 | 1 |
Net Income (GAAP) | -3 | 5 | -6 | -5 | -6 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 44 | 28 | 16 | 15 | 8 |
Depreciation & Amortization (Cash Flow) | 40 | 23 | 18 | 15 | 11 |
Income After Depreciation & Amortization | 4 | 5 | -1 | 1 | -3 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 39.77 | 37.22 | 30.44 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.07 | 0.13 | 0.08 | NA | NA |
Diluted Net EPS (GAAP) | -0.07 | 0.13 | -0.20 | -0.06 | -0.07 |
Fiscal Year end for Quipt Home Medical Corp falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 63.97 | 63.95 | 65.36 | 62.52 | 60.28 |
Cost Of Goods | 16.69 | 16.67 | 17.90 | 20.45 | 16.63 |
Gross Profit | 47.27 | 47.29 | 47.47 | 42.07 | 43.65 |
SG&A, R&D, and Dept/Amort Expenses | 46.88 | 46.10 | 46.10 | 41.01 | 43.49 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.39 | 1.19 | 1.37 | 1.06 | 0.16 |
Non-Operating Income | -0.20 | -0.41 | 0.22 | -0.32 | 0.44 |
Interest Expense | 1.89 | 1.89 | 1.96 | 1.90 | 1.97 |
Pretax Income | -1.70 | -1.10 | -0.37 | -1.25 | -1.36 |
Income Taxes | 0.00 | 0.26 | 0.22 | 0.08 | -0.32 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.70 | -1.37 | -0.59 | -1.33 | -1.03 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.70 | -1.37 | -0.59 | -1.33 | -1.03 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 42.62 | 42.19 | 39.31 | 44.20 | 40.58 |
Diluted EPS Before Non-Recurring Items | -0.04 | -0.03 | -0.01 | -0.03 | -0.03 |
Diluted Net EPS (GAAP) | -0.04 | -0.03 | -0.01 | -0.03 | -0.03 |